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Abstract
Background: Tuberculosis (TB) during pregnancy may lead to severe consequences affecting both mother and
child. Prenatal care could be a very good opportunity for TB care, especially for women who have limited access
to health services. The aim of this review was to gather and evaluate studies on TB care for pregnant women.
Methods: We used a combination of the terms “tuberculosis” and “pregnancy”, limited to human, to search for
published articles. Studies reflecting original data and focusing on TB care for pregnant women were included.
All references retrieved were collected using the Reference Manager software (Version 11).
Results: Thirty five studies were selected for review and their data showed that diagnosis was often delayed
because TB symptoms during pregnancy were not typical. TB prophylaxis and anti-TB therapy appeared to be safe
and effective for pregnant women and their babies when suitable follow up and early initiation were present, but
the compliance rate to TB prophylaxis is still low due to lack of follow up and referral services. TB care practices in
the reviewed studies were in line in principle with the WHO International Standards for Tuberculosis Care (ISTC).
Conclusions: Integration of TB care within prenatal care would improve TB diagnosis and treatment for pregnant
women. To improve the quality of TB care, it is necessary to develop national level guidelines based on the ISTC
with detailed guidelines for pregnant women.
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Background
According to the World Health Organization (WHO),
every year about 700,000 women die of tuberculosis (TB)
and over three million contract the disease [1]. TB is the
third leading cause of death among women aged 15–44. TB
can cause infertility and contributes to poor reproductive
health outcomes [2,3].
When pregnant women contract TB, the disease is more
difficult to diagnose because TB symptoms such as fatigue,
shortness of breath, sweating, tiredness, cough, and mild
fever are similar to physiological symptoms of pregnancy.
Untreated TB or TB treated late may lead to severe conse-
quences affecting both mother and child [4,5]. Pregnant
women with pulmonary TB who are treated appropriately
do not have increased rates of maternal or neonatal com-
plications, while without treatment, TB can lead to
increased neonatal morbidity, low birth weight, prematur-
ity, and increased pregnancy complications, including
four-fold increases in maternal morbidity due to higher
rates of abortion, post partum haemorrhage, labour diffi-
culties, and pre-eclampsia [5]. Prenatal care could be a
very good opportunity for TB screening and diagnosis and
for following up TB care, especially for women who have
limited access to health services, such as migrants or
women of limited social/economic status, who only ap-
proach medical services when pregnant [4,5].
The WHO Guidelines for Treatment of Tuberculosis
provide recommendations for TB care and recommend the
integration of TB care within both prenatal care procedures
and the Preventing Mother to Child Transmission of HIV
Program (PMTCT) in order to utilise existing health
resources and systems to improve accessibility and effect-
iveness of TB care for pregnant women and prevent the
mother to child transmission of TB [6].* Correspondence: hang.nguyen@marionegri.it
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Regardless of the importance of TB care in the prenatal
period, however, only a modest number of articles address-
ing TB in pregnant women have been published. Some
major controversial issues in TB care during pregnancy
remain that require further research, such as the safety,
reliability, and feasibility of TB screening methods used
in the prenatal period [7], drug therapy for pregnant MDR
women [8], and delay of treatment until the post partum
period in case of latent tuberculosis infection (LTBI) [9].
LTBI is a condition in which a person is infected with
Mycobacterium tuberculosis, but does not currently have
active tuberculosis disease.
This systematic review aimed to gather and evaluate
evidence based studies on TB care in pregnancy, with
consideration of WHO standard guidelines for TB care,
in order to recommend better practices to improve
TB care for pregnant women. For studies on TB care
in pregnancy the authors intended those addressing
screening/diagnosis, prevention, treatment, or follow-
up/supervision/counselling activities/services for women
in pregnancy.
Methods
The following databases were searched for articles in Eng-
lish, published in any year up to December 31, 2012: MED-
LINE (indexes articles dating back to 1946), EMBASE
(1973), the Cochrane Library (various), and www.clinical-
trials.gov (2000). The search strategies involved 1. using the
MeSH terms “tuberculosis” and “pregnancy”, limited to
human; 2. the terms “tuberc*” and “pregnan*” as free text
within articles indexed in the last 90 days, limited to hu-
man; 3. combining the results of MeSH “tuberculosis” and
free text “tuberc*”; 4. combining the results of MeSH “preg-
nancy” and free text “pregnan*”; 5. combining the results of
steps 3 and 4 (pregnancy AND tuberculosis, limited to
Human). The syntax was adjusted for the specific data-
bases. Reference lists were then searched for potentially
relevant articles.
Inclusion criteria
Studies reflecting original data and focusing on TB care
(screening, diagnosis, treatment, and follow up) in preg-
nant women.
Exclusion criteria
Articles were excluded if: 1. The target group was NOT
pregnant women, 2. TB was mentioned, but NOT TB care
(i.e. TB as a complication of other diseases, as part of a
study on infectious diseases, etc.); 3. Original data was not
included 4. They were NOT studies (letters, presentations,
conference documents, case reports).
Figure 1 summarizes the selection process for review ar-
ticles with detailed number of articles in each step.
Data extraction and assessment
All references retrieved were collected and analysed using
the Reference Manager (Version 11) program. All identified
abstracts were read for their applicability to inclusion and
Potentially appropriate 
articles to be evaluated  
1343
Total articles retrieved 2638 
(Embase 1162, Medline 1419, 
Cochrane Library 57, 
Clinicaltrials website 0)
Duplicates: 218
Total article abstracts to be 
reviewed 670
Editorials, letters, comments, 
conference abstracts/papers, notes, 
guidelines, reviews  673
Article content to be 
reviewed in detail 113
No authors and/or no abstracts  1077







Figure 1 PRISMA Flow diagram of search strategy.
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exclusion criteria by two co-reviewers and discrepancies
were resolved by a third reviewer. Potentially relevant
articles were obtained and examined, and the quality of se-
lected studies was assessed by two evaluators using the
checklists from the National Institute for Health and
Clinical Excellence (NICE)’s manual for developing public
health guidance [10] (See Additional file 1). Each study was
evaluated by the appropriate NICE checklist depends on
study type. The quality evaluation took into consideration
the studies’ internal and external validity. According to
NICE guidelines, a study was rated good quality (++) if it
fulfilled all or most of criteria in the check list, medium
quality if it fulfilled some (+), and low quality if few or no
criteria were fulfilled (−) [10]. Inter-reviewer reliability was
measured using Cohen’s Kappa statistics. Discrepancies
were addressed by a third reviewer. MS Excel software was
used to process data from the selected studies.
Details of ethics approval
This is a systematic review of previously published data
and therefore does not require ethical approval.
Results
Summary of included studies
Thirty five studies were selected for detailed review.
Good inter-rater agreement on the quality assessment of
the studies was found (K = 0.70). There were 6 studies
with good quality (++), 21 with medium quality (+), and
8 with low quality (−). The reasons to include studies
with low quality is the limited number of studies in se-
lected topics and one of the purpose of this review is to
have an overall evaluation on the situation of research
on TB care for pregnant women.
Table 1 shows the characteristics of the reviewed studies
and the quality evaluation scores. Concerning the study
types, there were 14 cohort studies, 8 before and after stud-
ies, 6 cross sectional studies, 4 case control studies, 2 con-
trolled trials, and 1 qualitative study.
Concerning the topics addressed, some studies addressed
multiple topics: 8 studies covered 2 topics and 1 study cov-
ered 3. The topic of TB diagnosis/screening was presented
in 21 studies, 14 studies addressed TB treatment (including
4 on MDR treatment), 2 studies were on TB prevention,
specifically on LTBI prophylaxis, and 3 studies were on the
follow-up of women’s compliance to the TB prophylaxis
therapy. All studies were published after 1975, with a
majority (26/35) published after 1999. Data originated from
16 different countries. Fifteen studies were carried out in
resource-rich countries: US (11 studies), UK (3), and the
Netherlands (1), while 20 were carried out in resource-
limited countries: South Africa (6 studies), India (3), and
the remaining countries had 1 each. One group of re-
searchers in South Africa conducted 3 studies [22,32,44],
other studies were all conducted by different groups of
researchers. In all, 81093 people were enrolled in these
studies, 37404 of whom in the study group (pregnant
women with TB) and 43689 in the controlled/comparison
groups (pregnant women without TB or/and non-pregnant
women with TB). The large total was mostly due to one
population based study involving 61016 people [14].
TB diagnosis and screening for pregnant women
The procedures for TB screening and diagnosis for preg-
nant women described in the reviewed studies include the
tuberculin sensitivity test (TST/PPD) followed by the spu-
tum test (Acid-fast bacillus - AFB) and the shielded chest
X-ray [18,19,23,24,30]. The AFB smear test appears to
have low sensitivity in pregnant women [18,19,30], but is
still used in low resource settings as part of the procedure
for diagnosing active TB due to its low cost and simple
technique [13,30]. AFB culture was used as a confirmation
of diagnosis, but is time consuming and not available in
low resource settings [13,23]. Another technique, fluores-
cence microscopy, was recommended as a substitute for
AFB culture because it is cheaper [13]. This procedure is
for pulmonary TB cases and cannot identify extra pul-
monary TB without additional tests and presence of phys-
ical TB symptoms. A clinical examination comprising a
questionnaire tracking TB history and detecting TB clin-
ical symptoms was also used and was proven to increase
reliability of TB screening and diagnosis when combined
with paraclinical tests [13,23,27,30,41]. Some authors rec-
ommended not using chest X-ray for pregnant women if
there were no clinical symptoms of TB [30].
TST is used widely as the first step in TB screening
and diagnosis and to identify LTBI [18]. Studies showed
that pregnancy does not affect the sensitivity of this test
[20], but its result can be affected by HIV infection or
any situation that severely weakens the immune system
(such as disseminated TB), as these could lead to false
negative results [21,30,45]. BCG vaccination can also
lead to TST positive results in healthy women [11,28].
In a high HIV prevalence setting, other tests and clinical
symptoms should therefore be taken into account in
diagnosing TB [41] and the TST and anergy skin tests
(the latter is used to evaluate whether the immune sys-
tem is functioning properly or not and can indicate
whether the results of the other skin test are reliable) are
recommended as a TB screening method in the prenatal
care procedures [31]. In populations in which the major-
ity of people are BCG vaccinated or their vaccination
status is uncertain, TST is discouraged and IGRA is rec-
ommended for TB screening and diagnosis [11,28].
Concerning the IGRA test, one study in Kenya com-
pared results of this test with the TST in screening for
TB and showed the advantage of the IGRA test over
TST in TB screening and diagnosis for HIV positive
pregnant women, since its sensitivity is not affected by
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Study type Topic No. of cases Length of study Country Quality score*
(from high to low)
1 Worjoloh et al./2011 [11] 5/2009 –
3/2010
Cross sectional Screening 220 10 months US ++
2 Sangala et al./2006 [12] 2006 Qualitative Screening 40 (15 pregnant, 15 non pregnant, 10
antenatal care providers)
N/A Malawi ++




3963 7 months South
Africa
++
4 Czeizel et al./2001 [14] 1980-1996 Case control Treatment 61016 (38151 controls and 22865 cases) 16 years Hungary ++
5 Tripathy et al./2003 [15] 1986-2001 Prospective cohort study Treatment 213 (111 pregnant with TB, 51 pregnant
without TB, 51 non pregnant with TB)
15 years India ++
6 Jana et al./1999 [16] 1983-1993 Case control Treatment 165 (33 pregnant with TB, 132 pregnant
without TB)
10 years India ++
7 Figueroa-Damian et al./
1998 [17]
1990-1995 Case control Treatment 100 (25 pregnant with TB, 75 pregnant
without TB)
5 years Mexico +
8 Carter et al. /1994 [18] 1987-1991 Retrospective cohort study Diagnosis 22 (7 pregnant, 15 nonpregnant) 4 years US +
9 Doveren et al./1998 [19] 1990-1996 Retrospective cohort study Diagnosis 14 (5 pregnant, 9 non pregnant) 6 years Netherlands +
10 Present et al./1975 [20] 1975 Non-randomized controlled trial Diagnosis 326 (167 pregnant, 226 non- pregnant) 1 year US +




Prospective cohort study Diagnosis 333 8 years Kenya +
12 Khan et al./2001 [22] 1996-1998 Prospective study cohort 1997–
1998, retrospective cohort study
1996
Diagnosis 101 3 years South
Africa
+
13 Knight et al./2009 [23] 2005-2006 Cross sectional Diagnosis 33 1 year UK +
14 Kothari et al./2006 [24] 1/1997-
12/2001
Before and after study Diagnosis,
treatment,
follow-up
32 5 year UK +
15 Kwara et al./2008 [25] 2003 Retrospective cohort study Follow up 845 (97 pregnant women) 1 year US +
16 Cruz et al./2005 [26] 2000 Retrospective cohort study Follow-up 425 1 year US +
17 Kali et al./2006 [27] 6/2003-
10/2003
Cross sectional Screening 370 4 months South
Africa
+
18 Sepulveda et al./1995
[28]
1991-1994 Prospective cohort study Screening 840 3 years Chile +
19 Meints et al./2010 [29] 2003-2006 Cross sectional Screening 1767 4 years US +
20 Sheriff et al./2010 [30] 6/2008-8/
2008)
Cross sectional Screening 286 2 months Tanzania +
21 Mofenson et al./1995 [31] 9/1989 -3/
1993
Prospective cohort study Screening,
diagnosis
183 (65 pregnant and 118 non-
pregnant)
3.5 years US and
Puerto Rico
+
22 Pillay et al./2001 [32] 1996-1998 Prospective cohort study Screening,
diagnosis






















Table 1 Characteristics of reviewed studies and quality evaluation results, sorted by quality evaluation score (Continued)
23 Margono et al./1994 [33] 1985-1992 Before and after study Screening,
diagnosis,
treatment
16 7 years US +
24 Lighter-Fisher et al./2012
[34]
2012 Non-randomized controlled trial Screening,
diagnosis
280 (140 pregnant women, 140 non
pregnant women)
N/A US +
25 Donald et al./1991 [35] 1991 Retrospective cohort study Treatment 30 children with mothers who received




26 Palacios et al./2009 [36] 1996
-2005
Before and after study Treatment
(drug resistant)
38 10 years Peru +
27 Tabarsi et al./2011 [37] 2003-2009 Before and after study Treatment
(drug resistant)
5 6 years Iran +
28 Cheng et al./2003 [38] 2002 Before and after study Diagnosis,
treatment






29 Franks et al./1989 [39] 1980-1982 Case control Prevention 7629 (3681 pregnant, 3948 non-
pregnant)
18 months US -
30 Sackoff et al./2006 [40] 1999-2000 Retrospective cohort study Prevention,
follow-up
730 1 year US -
31 Gupta et al./2011 [41] 2002-2007 Retrospective cohort study Screening 799 5 years India -
32 Keskin et al./2008 [42] 2000-2005 Before and after study Treatment 5 5 years Turkey -
33 De Oliveira et al./2011
[43]
1995-2007 Before and after study Treatment
(drug resistant)
7 13 years Brazil -
34 Khan et al./2007 [44] 1996-2001 Before and after study Treatment
(drug resistant)
5 5 years South
Africa
-
35 Llewelyn et al./2000 [45] 12/1995-
5/1998
Prospective cohort study Diagnosis,
treatment
13 30 months UK -




















HIV infection [21]. Two studies proved the value of
IGRA in detecting LTBI in pregnant women, since the
results of this test were not affected by BCG vaccination,
thus avoiding the TST false positive result and the un-
necessary, consequent INH prophylaxis [11,21].
Prevention
TB prevention includes BCG vaccination in childhood
and INH prophylaxis for LTBI positive people. There were
2 studies on TB prevention and both were on INH
prophylaxis for LTBI pregnant women. Both were con-
ducted in the US with pregnant women of foreign origin
and LTBI was diagnosed by TST [39,40]. One study [40]
showed a low completion rate of INH therapy ( 9.3% ) and
the other showed a high risk of INH toxic hepatitis, with
pregnant women having a 2.5 fold greater risk of INH
hepatitis than non-pregnant women (but this result was
not statistically significant due to the small number of
women) [39]. The 2 studies found that the main reason
for this discouraging result was a lack of follow up and re-
ferral services for pregnant women undergoing INH
prophylaxis [39,40].
Treatment
There were 375 pregnant women with TB in the 14
studies on TB treatment. Treatment outcome was gener-
ally positive, with 332/375 women cured (confirmed by
AFB culture conversion). In terms of mortality, 25
women died during treatment, 11 of whom died due to
meningitis TB, 11 due to MDR-TB, 2 due to acute re-
spiratory distress syndrome (ARDS), and 1 due to a non-
TB related reason (massive pulmonary embolism). Other
than mortality, the negative treatment outcomes in-
cluded 4 treatment failures, 4 cases of residual functional
deficit, 7 treatment terminations due to adverse drug ef-
fects, and 3 cases of treatment abandonment.
In terms of pregnancy outcome, only 11 women chose
to terminate the pregnancy when they discovered their
TB situation, while the others continued the pregnancy
and underwent TB therapy. Among the pregnant women
undergoing TB therapy, 332 women gave birth, 1 had a
therapeutic abortion, 3 had miscarriages, 3 had still-
borns, and 25 died. Concerning the 332 cases of mothers
who gave birth, 4 infants died shortly after birth due to
pneumonia and prematurity, 2 were HIV positive, 1 had
active TB, 2 had LTBI, 50 were low birth weight, and 7
had growth restriction. Studies also showed that HIV in-
fected women were more likely to choose pregnancy ter-
mination and had higher mortality and morbidity rates,
even with intensive TB treatment combined with HIV
treatment [33,44].
The first line drugs used for pregnant women in the
studies included INH, ethambutol (ETB), rifampicin (RIF),
and, in some cases of extra pulmonary TB, pyrazinamid
(PZA) [15,19,33,45]. In the MDR cases, the second line
drugs, including drugs of the amino glycosides group,
fluoroquinolone, thioamides, cycloserines, and terizidone,
were used in combination with effective first line drugs,
and the treatment regime depended on the drug resistance
situation of the individual cases [36,37,43,44].
Regarding effectiveness and safety of anti-TB drugs,
results of the reviewed studies showed no significant
association between child abnormality and mother’s
exposure to anti-TB drugs, both for 1st and 2nd line anti-
TB drugs during pregnancy [14,15,37,43,44]. Other sig-
nificant adverse effects were recorded in a very small
number of pregnant women (2 cases of drug induced
hepatitis, 2 of PZA allergy, 2 of sensorineural deafness,
and 1 of severe nausea and jaundice) and led to termin-
ation of therapy without mortality [24,44]. Streptomycin
(SM) was not used in any studies because of its potential
risk of deafness in babies. However, a retrospective study
was conducted, checking the hearing capacity of 30 chil-
dren whose mothers received SM injection during preg-
nancy, and found no significant effect, with only one
case of deafness possibly linked to the mother’s use of
SM. Authors of this study recommend only using SM
after the 2nd trimester if really necessary [35].
There were 4 studies with 55 pregnant women on MDR
treatment. Unlike other studies, in these TB was detected
in all the women before pregnancy. More specifically, 48/
55 of the women had been diagnosed with MDR TB and
had already taken 2nd line anti-TB drugs before getting
pregnant, while 7/55 were diagnosed MDR TB and started
therapy during pregnancy [36,37,43,44]. After being coun-
selled by clinicians, only 6/55 women chose abortion,
while the rest decided to continue the pregnancy and
undergo MDR therapy [37,44]. Eleven women died (8 died
during treatment and 3 died after completing treatment
for unknown reasons). There was one stillbirth and one
child died prematurely due to pneumonia. One woman
and her child were lost to follow up. One woman had to
terminate treatment due to hepatitis. Other cases were
treated successfully. The results of the studies showed
that, with an attentive follow-up and appropriate therapy,
MDR-TB pregnant women can be cured and have a posi-
tive maternal outcome, and should therefore be given the
option to continue with a pregnancy [36,37,44]. The
results also showed that a delay in, or default, MDR treat-
ment were the main causes of mortality and morbidity for
mothers and babies [36,43,44].
Follow-up
Follow-up actions for TB therapy include checking for a
woman’s drug consumption, clinical symptoms of anti-
TB drug adverse effects, and liver function tests. Good
compliance with TB treatment in pregnant women led
to better maternal outcome and TB recovery rate. These
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studies showed that adequate health services and directly
observed therapy (DOT) could greatly contribute to
women’s compliance, and, therefore, to treatment suc-
cess [36,45].
There were 3 studies on follow-up of TB therapy for
pregnant women and all were on INH prophylaxis. Preg-
nant women with LTBI were offered 6 months of prophy-
laxis with INH. The compliance rate was low, possibly due
to the women’s concern about hepatitis and other adverse
effects [25,40], and the lack of referral services for treat-
ment evaluation and action from health care providers to
ensure compliance [40]. Compared to the general popula-
tion, pregnant women were less likely to initiate the INH
prophylaxis – 52.1% vs 14.7% [25]. In all 3 studies, the com-
pletion rate among pregnant women was very low (14.7%,
9.3%, and 21.2%) [25,26,40]. All studies recommended that
health care providers implement better follow-up strategies
to increase patient compliance in the prenatal and post-
partum periods, ensure follow-up of drug adverse effects,
and not dispense INH quantities covering more than
30 days of treatment at each visit.
Discussion
Main findings
In resource-rich countries, pregnant women with high TB
prevalence are migrants and people of foreign origin
[11,18,23,24,28,45], while in resource-limited countries,
HIV infected pregnant women are the group with high TB
prevalence and mortality [13,22,27,32,41].
The major problem concerning TB diagnosis for preg-
nant women is the delay in diagnosis, with a median
delay time, defined as the duration from symptom onset
to confirmation of diagnosis, ranging from 7 days to
6 months. The main reasons for this delay are that
women seek health services and prenatal care at a late
stage of their pregnancy and that TB during pregnancy
is asymptomatic or has nonspecific symptoms, especially
in cases of extra pulmonary TB [18,23,38,45]. Compared
to non-pregnant women, pregnant women were more
likely to be diagnosed with TB via routine screening (as
part of prenatal care) [30]. In HIV infected people, the
difficulty in diagnosis is even greater since the weak im-
mune reaction may cause false negative TST and make
early TB symptoms unclear [21,32]. Thus, all studies rec-
ommended the integration of TB screening in prenatal
care procedures for high risk groups.
In terms of treatment, studies have shown the import-
ance of starting treatment as soon as possible, even before
TB culture results, to revert the negative impact of TB on
mothers and babies [17,24,33,45]. Early treatment of TB
(1st and 2nd trimester) led to a maternal outcome compar-
able to that of non-TB infected pregnant women, and to a
much better outcome than that of women who received
late treatment [17]. Authors also recommended making
TB culture mandatory since it is the most reliable stand-
ard for confirming TB infection and treatment effective-
ness, and for revising the therapy in case of lack of success
[15,33]. Treatment of extra PTB had a less positive prog-
nosis than PTB due to greater difficulty in diagnosis and
treatment [16,38]. If women are diagnosed and treated
with anti-TB early, however, the maternal outcome can be
positive [16,24,33,45].
The low LTBI treatment completion rates raised con-
cerns about LTBI prophylaxis during pregnancy. Follow
up actions for LTBI in reviewed studies required women
go to the health clinics for check-ups and to obtain more
medication, but no onsite enforcement in the commu-
nity/family, such as DOT or visits, was provided to
reinforce patient compliance [25,26,40]. These studies
showed the importance of health services in follow-up,
since pregnant women who receive health care from the
same clinician before and after delivery, who have insur-
ance, or who receive continuous care from clinics out-
side hospitals were more likely to complete the therapy
[25,26].
Strengths and limitations
The strength of the review is that all aspects of TB care in
different settings were considered and reviewed and that
the authors could therefore use the WHO ISTC as a
standard to which to compare TB care practices. However,
the review has some limitations. The studies reviewed
were of limited quality and covered multiple aspects of TB
care, no intensive analysis for each aspect could therefore
be performed. There was a limited number of population-
based studies, since most were conducted in a single
clinic. Results are therefore not solid enough to be applic-
able to a larger population. Another limitation was that
few studies had control groups; some used comparison
groups that were not fully comparable with the study
group [16-18,20,25,28,31,39]. Furthermore, the study de-
signs were weak, since no randomised controlled trials
were present. Only one qualitative study was found, and
with a disease related to socio-economic status and pov-
erty as is TB, additional qualitative studies would have
been useful in identifying attitudes, behaviours, challenges,
and opportunities for shaping effective interventions/
policies for better care for TB patients. A more general
limitation is that the differing resources available between
different countries make it difficult to generalise the
conclusions.
Interpretation
According to the WHO guidelines, the ISTC applies to the
general population, with only a notion on avoiding using
streptomycin in treatment during pregnancy [6,46]. In
principle, TB care practices in the reviewed studies were
consistent with the ISTC. However, in resource-limited
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countries some standards could not be put into practice
(See Additional file 2).
Since the WHO guidelines focus on resource-limited
countries with high TB prevalence, these may not be en-
tirely appropriate for resource-rich countries. The compari-
son with the ISTC also revealed that, althoughTB diagnosis
and treatment facilities in resource-rich countries are better,
the role of counselling and support/supervision has not
drawn enough attention on the part of health care
providers and researchers in such countries, albeit WHO
considers these as important standards to ensure patient
compliance to TB treatment.
Conclusions
Review results have proven both the importance of TB care
in reducing TB mortality and morbidity for women and
their babies, and the feasibility of TB control interventions,
even in limited resource settings. Several recommendations
to improve the quality of TB care for pregnant women can
be made based on the results of the review:
TB care for pregnant women should utilise available
health system resources, especially the antenatal care
programs, and should include the patient-centred approach
in counselling, supervision, and support as well as a well-
managed, nation-wide method of treatment record keeping
to ensure patients’ compliance to TB treatment.
Concerning the target of TB care, in resource-rich coun-
tries screening interventions should focus on the foreign
origin population, while in resource-limited countries inter-
ventions should focus on areas with low socio-economic
status and high prevalence of HIV infection.
Raising doctors’ awareness on TB is fundamental.
When visiting women with unclear symptoms such as
fever, doctors should consider TB and investigate the
woman’s history and prescribe TB tests in order not to
delay diagnosis and to avoid severe consequences.
Concerning TB diagnostic tests, considering the low
sensitivity of the AFB smear test in diagnosis for preg-
nant women and the advantage of the IGRA test over
the AFB smear test, IGRA is recommended in diagnosis
and screening if possible. Further studies are therefore
needed on its specificity and reliability, and on its applic-
ability to a wider population.
Additional studies on TB therapies for pregnant women
should be performed, given their scarcity, especially for
MDR TB.
Before deciding to start the TB preventive therapy, BCG
vaccination status should be confirmed, and during
therapy, the test to detect INH adverse effects should be
conducted regularly. More active involvement of health
care providers in following up women’s compliance could
improve the low completion rate of therapy.
Information on individual/family history of TB infec-
tion, BCG vaccination, and past treatment, for example,
were hardly collected. Collecting such information from
patients during the first visit and giving this step high
priority could help to improve diagnosis and treatment.
Additional studies, both qualitative and quantitative, and
clinical and community-based, need to be performed and
should not only address the quality of TB care provided by
service providers, but also the behaviours and attitudes of
individuals and communities in approaching and using
available health services and the barriers faced in accessing
and complying with TB treatment. It would be especially
important to address issues such as carrying out TB
cultures, for which patients then have to return to the clinic
for the results, and following up for INH toxicity, since in
poor resource settings travelling, for example, is a signifi-
cant barrier for patients. National TB care guidelines based
on the ISTC with detailed guidelines for TB care for
pregnant women are necessary. Improvement in TB care
for pregnant women will contribute significantly to achiev-
ing the Millennium Development Goal target of halting TB
by 2015 and beginning to reverse the incidence of TB [47].
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